The Safety, Tolerability, and Pharmacokinetics & Pharmacodynamics of Multiple- Dose TNT009 in Patients With Chronic Immune Thrombocytopenia (ITP)

Trial Profile

The Safety, Tolerability, and Pharmacokinetics & Pharmacodynamics of Multiple- Dose TNT009 in Patients With Chronic Immune Thrombocytopenia (ITP)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Sep 2017

At a glance

  • Drugs TNT 009 (Primary)
  • Indications Idiopathic thrombocytopenic purpura
  • Focus Adverse reactions
  • Sponsors True North Therapeutics
  • Most Recent Events

    • 11 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top